BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

DR Cysteamine cysteamine bitartrate: Phase III data

Additionally, the mean total daily, steady-state dose of DR Cysteamine was 82% of patient's incoming dose of Cystagon. There was one serious adverse event of gastric intolerance determined to be "possibly related" to DR Cysteamine and was subsequently resolved. DR Cysteamine has Orphan Drug designation...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >